BioCentury | Feb 19, 2016
Financial News

Micreos secures EUR 12M

...resistance. CEO Mark Offerhaus told BioCentury Micreos would use the funds to support development of Staphefekt...
...infections and chronic wounds associated with S. aureus infection. Micreos already markets a formulation of Staphefekt...
BioCentury | Dec 11, 2014
Targets & Mechanisms

Lysin in wait

...clinically viable lysin formulation acceptable for systemic exposure. The company already has a marketed lysin- Staphefekt XDR.300-that...
...it is not sufficiently pure for systemic exposure. Micreos is developing a new formulation of Staphefekt...
...of the antibiotic Centany mupirocin or Staphefekt developed resistance to the antibiotic but not to Staphefekt...
Items per page:
1 - 2 of 2